Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.

Pape UF, Berndt U, Müller-Nordhorn J, Böhmig M, Roll S, Koch M, Willich SN, Wiedenmann B.

Endocr Relat Cancer. 2008 Dec;15(4):1083-97. doi: 10.1677/ERC-08-0017. Epub 2008 Jul 4.

2.

Alpha-fetoprotein and human chorionic gonadotrophin-beta as prognostic markers in neuroendocrine tumour patients.

Shah T, Srirajaskanthan R, Bhogal M, Toubanakis C, Meyer T, Noonan A, Witney-Smith C, Amin T, Bhogal P, Sivathasan N, Warner B, Hochhauser D, Caplin ME.

Br J Cancer. 2008 Jul 8;99(1):72-7. doi: 10.1038/sj.bjc.6604428. Epub 2008 Jun 24.

3.

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB.

J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377. Review.

PMID:
18565894
4.

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.

Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Röcken C, Rindi G, Wiedenmann B.

Cancer. 2008 Jul 15;113(2):256-65. doi: 10.1002/cncr.23549.

5.

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.

Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J.

Endocr Relat Cancer. 2007 Jun;14(2):221-32. Review.

6.

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B.

Clin Cancer Res. 2007 May 15;13(10):2986-91.

7.

Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours.

Toumpanakis C, Meyer T, Caplin ME.

Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):131-44. Review.

PMID:
17382269
8.

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B; all other Frascati Consensus Conference participants.; European Neuroendocrine Tumor Society (ENETS)..

Virchows Arch. 2006 Oct;449(4):395-401. Epub 2006 Sep 12.

9.

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS.

J Clin Oncol. 2006 Jan 20;24(3):401-6.

PMID:
16421420
10.

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG; Eastern Cooperative Oncology Group..

J Clin Oncol. 2005 Aug 1;23(22):4897-904.

PMID:
16051944
11.

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.

Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC.

J Clin Oncol. 2004 Dec 1;22(23):4762-71. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570077
12.

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors.

Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS.

Cancer. 2004 Sep 1;101(5):934-9.

13.

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.

Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK.

Cancer. 2001 Sep 1;92(5):1101-7.

PMID:
11571721
14.

A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.

Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J.

Cancer. 2001 Apr 15;91(8):1543-8.

PMID:
11301403
15.

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.

Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P.

Br J Cancer. 1999 Dec;81(8):1351-5.

17.

Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.

Moertel CG, Hanley JA, Johnson LA.

N Engl J Med. 1980 Nov 20;303(21):1189-94.

PMID:
6252466
18.

Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor.

Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO Jr.

J Clin Oncol. 1984 Nov;2(11):1255-9.

PMID:
6238136
19.

A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study.

Bukowski RM, Johnson KG, Peterson RF, Stephens RL, Rivkin SE, Neilan B, Costanzi JH.

Cancer. 1987 Dec 15;60(12):2891-5.

Supplemental Content

Support Center